Articles tagged "Survival"

2019 American Transplant Congress
Leukopenia in Older Kidney Transplant Recipients is Associated with Decreased Allograft Survival and Increased Patient Survival
R. Rodriguez, A. Price, K. Soliman, R. Vinaya, D. Lazarus, M. Casey, M. Labonte, L. Erbe, M. Shearer, D. Taber, M. Posadas Salas
Transplant Nephrology, Medical University of South Carolina, Charleston, SC
*Purpose: Older kidney transplant recipients are vulnerable to side effects of immunosuppression (IS) including leukopenia. Providers often reduce MMF dose in response to leukopenia. This…
2019 American Transplant Congress
Outcomes of Liver Transplantation for Hepatocellular Carcinoma in Septuagenarians
M. Najjar¹, K. Bruestle¹, P. Jiang¹, E. Lieberman¹, R. Hwang¹, A. Mathur¹, E. C. Verna¹, A. Griesemer¹, B. Samstein², T. Kato¹, Y. M. Saenger¹, K. J. Halazun², J. C. Emond¹
¹Columbia University Medical Center, New York, NY, ²Weill Cornell Medicine, New York, NY
*Purpose: The impact of advanced age on liver transplantation (LT) for hepatocellular carcinoma (HCC) has not been well studied. We sought to compare post-OLT survival…
2019 American Transplant Congress
Diminishing Scientific Registry of Transplant Recipients Risk-Adjusted Mortality: Reaction to Flagging, Artifact of Modeling, or Both?
J. A. Gregg¹, K. L. Womer¹, A. Santos¹, S. J. Moore², K. A. Andreoni³
¹Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville, FL, ²Shands Transplant Center, University of Florida, UF Health Shands, Gainesville, FL, ³Department of Surgery, University of Florida, Gainesville, FL
*Purpose: To examine longitudinal trends in SRTR risk-adjusted patient and graft survival rates.*Methods: Current, and archived versions of The Scientific Registry of Transplant Recipients (SRTR)…
2019 American Transplant Congress
Aorto-Iliac Calcification is a Risk Factor for Inferior Patient and Graft Survival in Kidney Transplant Recipients; A Systematic Review and Meta-Analysis
A. A. Rijkse, J. L. van Dam, H. J. Kimenai, J. N. IJzermans, R. C. Minnee
HPB/Transplant surgery, Erasmus Medical Center, Rotterdam, Netherlands
*Purpose: While the incidence of transplanting a kidney onto atherosclerotic iliac arteries is becoming more common, little is known about the clinical outcome. We performed…
2019 American Transplant Congress
Normothermic Ex-Situ Liver Perfusion Parameters of Liver Viability in a Porcine Model of Liver Transplantation with Marginal Grafts
I. Linares-Cervantes¹, J. Echeverri¹, S. Cleland¹, M. Kaths¹, R. Rosales¹, T. Goto¹, D. Kollmann¹, M. Hamar¹, P. Urbanellis¹, L. Mazilescu¹, S. Ganesh¹, O. Adeyi¹, P. Yip¹, B. Bojko², P. Gorynzka², K. Gorynski², D. Grant¹, N. Selzner¹, M. Wasowicz¹, M. Selzner¹
¹Toronto General Hospital, Toronto, ON, Canada, ²University of Nicolaus Copernicus, Torun, Poland
*Purpose: Evaluate parameters of liver viability during normothermic ex-situ liver perfusion (NEsLP) prior to transplantation.*Methods: In this study, we investigated prior assessed parameters and new…
2019 American Transplant Congress
A National Cohort Validation of Graft Outcomes of Elderly Kidney Transplant Recipients
I. Bajjoka, A. Yaldo, C. Crombez, M. Abouljoud
Henry Ford Transplant Institute, Detroit, MI
*Purpose: Previous analyses comparing elderly kidney transplant recipients (KTR) to younger KTR found that elderly patients suffered higher rates of mortality, less biopsy-proven acute rejection…
2019 American Transplant Congress
Policy Changes in Liver Graft Allocation for Hepatocellular Carcinoma in the USA: Improved Survival for African American Recipients
M. Molinari¹, D. Jorgensen¹, A. Tevar¹, C. Hughes¹, A. Humar¹, N. Jonassaint²
¹Surgery, University of Pittsburgh Medical Centre, Pittsburgh, PA, ²Medicine, University of Pittsburgh Medical Centre, Pittsburgh, PA
*Purpose: To evaluate the effect of policy changes in liver graft allocation for hepatocellular carcinoma (HCC) on the overall survival of patients of different ethnicities…
2018 American Transplant Congress
Impact of Antecedent Malignancy on Kidney Transplant Outcomes: Patient, Graft, and Cancer-Free Survival
O. Serrano,¹ S. Mongin,² D. Berglund,¹ D. Vock,³ S. Chinnakotla,¹ T. Dunn,¹ E. Finger,¹ R. Kandaswamy,¹ T. Pruett,¹ A. Matas.¹
¹Surgery, University of Minnesota, Minneapolis, MN; ²Biostatistical Design and Analysis Center, Clinical and Translational Science Institute, Minneapolis, MN; ³Biostatistics, University of Minnesota, Minneapolis, MN.
OBJECTIVE: Non-skin pretransplant malignancy (NSPTM) has historically been considered a relative contraindication to kidney transplantation (KT). In addition to the conventional risk factors for cancer,…
2018 American Transplant Congress
A Low Level of De Novo DSA Sialylation is Associated with a Decreased of Allograft Survival in Non-Sensitized Kidney Transplant Recipients
M. Bonnet,^1,2 V. Pernin,^1,3 J-.E. Serre,¹ V. Georgescu,⁴ M. Le Quintrec,^1,2,3 G. Mourad,^1,2 J-.F. Eliaou,^2,5 C. Rene.^2,5
¹Nephrology, Dialysis and Transplantation, Hôpital Lapeyronie, Montpellier University Hospital, Montpellier, France; ²University of Medicine, Montpellier University, Montpellier, France; ³Inserm U1183, IRMB, Hôpital Saint Eloi, Montpellier University Hospital, Montpellier, France; ⁴Department of Medical Information, Montpellier University Hospital, Montpellier, France; ⁵Department of Immunology, Hôpital Saint Eloi, Montpellier University Hospital, Montpellier, France.
Background. In kidney transplantation, de novo donor specific antibodies (dnDSA) are associated with antibody-mediated rejection (ABMR) and graft failure. While appearance of dnDSA, there is…
2018 American Transplant Congress
MELD Based Allocation Deteriorates Patient Survival without Improving Waiting List Mortality in a Low Donor Area
P. Ritschl, L. Wiering, F. Aigner, M. Biebl, D. Eurich, M. Schmelzle, I. Sauer, K. Kotsch, J. Pratschke, R. Öllinger.
Department of Surgery, Campus Charité Mitte / Campus Virchow-Klinikum CCM/CVK, Charité - Universitätsmedizin Berlin, Berlin, Germany.
The MELD-based allocation system has been implemented in Germany in 2006 in order to decrease waiting list mortality in patients with end stage liver disease.…